Drugs

Name	Class	Trials
Acalabrutinib	Bruton's tyrosine kinase (BTK) inhibitor	122
Adalimumab	TNF inhibitor; monoclonal antibody	352
Aflibercept	Antineovascularization agent	174
Atezolizumab	Antineoplastic monoclonal antibody; PD-L1 inhibitor	586
Bevacizumab	Monoclonal antibody; angiogenesis inhibitor	1750
Carboplatin	Platinum-based antineoplastic	2332
Cisplatin	Platinum-based antineoplastic	2356
Cocaine	Local anesthetic; stimulant; SNDRI	22
Daratumumab	Human monoclonal antibody targeting CD38	260
Dexamethasone	Fluorinated glucocorticoid corticosteroid	2117
Docetaxel	Taxane chemotherapy	1615
Fentanyl	Synthetic opioid analgesic	454
Gemcitabine	Antimetabolite (nucleoside analogue)	1488
Liraglutide	GLP-1 receptor agonist	317
Metformin	Biguanide antihyperglycemic agent	1304
Methamphetamine	CNS stimulant (serotonin-norepinephrine-dopamine releasing agent)	13
mRNA-1010	Investigational mRNA seasonal influenza vaccine	12
Nab-paclitaxel	Taxane mitotic inhibitor (albumin-bound paclitaxel)	558
Nivolumab	PD-1 blocking antibody	1348
Orforglipron	Oral non-peptide GLP-1 receptor agonist	36
Paclitaxel	Taxane mitotic inhibitor	2163
Palbociclib	Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor	244
Pembrolizumab	PD-1 (programmed death receptor-1) blocking antibody	2001
Psilocybin	Serotonergic psychedelic hallucinogen; serotonin receptor agonist	173
Retatrutide	Investigational triple hormone receptor agonist (GIP/GLP-1/glucagon)	19
Rituximab	CD20-directed cytolytic monoclonal antibody	1662
Semaglutide	Glucagon-like peptide-1 (GLP-1) receptor agonist	376
Tirzepatide	Dual GIP receptor and GLP-1 receptor agonist	203
Venetoclax	B-cell lymphoma-2 (BCL-2) inhibitor	575